Production and Characterization of a Novel OX40 Ligand for Clinical Use
Abstract
The goals of the first year/phase of the DOD funded research, PC073499, have been accomplished. We produced two human versions of the OX40 ligand:trimer:Ig protein. The two protein constructs have different human trimer domains (TRAF2 and Matrillin-4), which confer differing folding patterns within the two-dimension structure of the protein. Both the TRAF2 and Matrilin-4 trimer domain constructs appear to have as good if not better in vitro bioactivity when compared to a mouse anti-human OX40 Ab that is currently in a clinical trial for cancer patient treatment. We have produced enough purified material to test the in vivo activity of these proteins and have planned a pilot study involving injection of these new human OX40 agonists in non-human primates. Upon completion of this project we will have important preclinical information that should allow for FDA approval of a fully human OX40 agonist to be tested in a clinical trial.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2009
- Accession Number
- ADA517909
Entities
People
- Andrew D. Weinberg